(19)
(11) EP 2 132 209 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.04.2014 Bulletin 2014/16

(45) Mention of the grant of the patent:
12.02.2014 Bulletin 2014/07

(21) Application number: 08718797.7

(22) Date of filing: 19.03.2008
(51) International Patent Classification (IPC): 
C07D 473/18(2006.01)
A61P 37/00(2006.01)
 A61K 31/522(2006.01)
(86) International application number:
PCT/GB2008/000958
(87) International publication number:
WO 2008/114008 (25.09.2008 Gazette 2008/39)

(54)

9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS

9-SUBSTITUIERTE 8-OXOADENINVERBINDUNGEN ALS MODULATOREN DES TOLL-LIKE-REZEPTORS (TLR7)

COMPOSÉS 8-OXO-ADENINE 9 SUBSTITUÉ COMME MODULATEURS DU RÉCEPTEUR DE TYPE TOLL (TLR7)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 19.03.2007 US 895529 P

(43) Date of publication of application:
16.12.2009 Bulletin 2009/51

(73) Proprietors:
  • AstraZeneca AB
    151 85 Södertälje (SE)
  • Dainippon Sumitomo Pharma Co., Ltd.
    Osaka 541-8524 (JP)
    Designated Contracting States:
    CH DE ES FR GB HR IS IT LI LT LV MT NO PL SE 

(72) Inventors:
  • BONNERT, Roger, Victor
    Loughborough Leicestershire LE11 5RH (GB)
  • MCINALLY, Thomas
    Loughborough Leicestershire LE11 5RH (GB)
  • THOM, Stephen
    Loughborough Leicestershire LE11 5RH (GB)

(74) Representative: Curran, Sally Ann et al
AstraZeneca Intellectual Property, Alderley Park
Macclesfield, Cheshire SK10 4TG
Macclesfield, Cheshire SK10 4TG (GB)


(56) References cited: : 
EP-A- 1 728 793
WO-A1-2007/034882
 WO-A1-2007/034881
WO-A1-2007/034916
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).